Laurus Labs Reports 126% Profit Growth, Acquires Stakes in Galenvs Sciences and SI C Resins
Laurus Labs reported a 126% rise in Q2 FY27 net profit to ₹441 crore, with revenue increasing 33% to ₹2,206 crore, driven by strong growth in its CDMO and Affordable Medicines divisions. EBITDA rose 78% to ₹762 crore, with margins expanding to 34.5%. The company announced acquisitions of a 60% stake in Canada-based Galenvs Sciences, specializing in oligonucleotides, and a 52% stake in SI C Resins to enhance peptide and oligonucleotide capabilities. CEO Satyanarayana Chava highlighted operational expansions and strategic investments to meet rising demand.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (73/100). Lens Score 37/100.
Outlets measured: thehindu, freepressjournal, moneycontrol, freepressjournal. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (65–78/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
freepressjournal broke this story on 29 Oct, 11:12 am. Other outlets followed.